Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Crinetics Pharmaceuticals (CRNX) Stock Price & Analysis
428 Followers
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.76 - $53.70
Previous Close$46.07
Volume1.25M
Average Volume (3M)945.80K
Market Cap
$3.63B
Enterprise Value$2.78B
Total Cash (Recent Filing)$900.96M
Total Debt (Recent Filing)$52.50M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 09, 2024EPS Estimate
-$0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding78,859,510
10 Day Avg. Volume810,543
30 Day Avg. Volume945,796
Standard Deviation0.16
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.67
Price to Sales (P/S)5616.28
Price to Cash Flow (P/CF)-23.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.41K
Enterprise Value/Gross Profit693.89
Enterprise Value/Ebitda-11.34
Forecast
1Y Price Target
$70.73Price Target Upside55.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Crinetics Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAtumelnant delivers impressive efficacy in normalizing hormone levels in treating CAH and ADCS.
Market PotentialCRNX's opportunity in ADCS should not be overlooked, especially since the Phase 1b/2a trial is being conducted with ADCS experts at the National Institutes of Health (NIH).
Patient OutcomesIn Cushing's trial, all treated patients reported improvement or even resolution in key symptoms associated with Cushing's, such as white cell counts and hypertension.
Bears Say
Clinical TrialsAll five patients on once-daily 80 atumelnant for 10 days experienced biochemical evidence of adrenal insufficiency by Day 2 of treatment.
Financial PerformanceCrinetics reported a net loss of $66.9 million, or $0.93 per share, during Q1 2024, compared to a net loss of $46.0 million, or $0.85 per share, during Q1 2023.
Product RisksAtumelnant is working and normalizing urinary free cortisol but also causing adrenal insufficiency that requires GC replacement.
---
Ownership Overview
9.61% Insiders
26.49% Mutual Funds
11.94% Other Institutional Investors
51.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $15.76 and its highest was $53.70 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Aug 09, 2024 which is in 37 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.81 by -$0.12.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.86.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 78,859,510 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.81. Following the earnings report the stock price went down -2.873%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 245M.
---
Crinetics Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.73 (55.31% Upside)
$70.73 (55.31% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 596.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
155.66%
12-Months-Change
Fundamentals
Return on Equity
-40.76%
Trailing 12-Months
Asset Growth
211.50%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q1 2024
0:00 / 0:00
---
CRNX Stock 12 Month Forecast
Average Price Target
$70.73
▲(55.31% Upside)
Technical Analysis
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+65.14%
reiterated a buy rating last month
Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +65.14% per trade.
---